Salvage therapy for invasive aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue SUPPL. 1, 2008, Pages 41-44

  Dockrell, D H ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amphotericin B; Antifungal invasive fungal infections; Caspofungin; Posaconazole; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; DRUG EFFECT; HUMAN; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; SALVAGE THERAPY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG RESISTANCE, FUNGAL; HUMANS; SALVAGE THERAPY;

EID: 41949133198     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm426     Document Type: Article

References (21)

1. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-33.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803; quiz 804-5.
3. Ribrag V, Dreyfus F, Venot A et al. Prognostic factors of invasive pulmonary aspergillosis in leukemic patients. Leuk Lymphoma 1993; 10: 317-21.
4. Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-9.
5. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
6. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neu-tropenia. J Clin Oncol 2001; 19: 253-9.
7. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. New Engl J Med 1999; 340: 764-71.
8. Bennett JE. Salvage therapy for aspergillosis. Clin Infect Dis 2005; 41 Suppl 6: S387-8.
9. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155: 1093-8.
10. Patterson TF, Boucher HW, Herbrecht R et al. Strategy of follow-ing voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448-52.
11. Kartsonis NA, Saah AJ, Lipka Joy C et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005; 50: 196-205.
12. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
13. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002; 347: 408-15.
14. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
15. Baden LR, Katz JT, Fishman JA et al. Salvage therapy with vori-conazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-7.
16. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
17. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutro-penic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
18. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
19. Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
20. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, non-comparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-97.
21. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005; 309: 2185-9.